Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Kidon, Mona (10339388800)"

Filter results by typing the first few letters
Now showing 1 - 6 of 6
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    An EAACI Task Force report on allergy to beta-lactams in children: Clinical entities and diagnostic procedures
    (2021)
    Blanca-Lopez, Natalia (16835888500)
    ;
    Atanaskovic-Markovic, Marina (6506020842)
    ;
    Gomes, Eva R. (7102464240)
    ;
    Kidon, Mona (10339388800)
    ;
    Kuyucu, Semanur (6602727782)
    ;
    Mori, Francesca (58041318500)
    ;
    Soyer, Ozge (24483981200)
    ;
    Caubet, Jean-Christoph (36460677400)
    Beta-lactam (BL) allergy suspicion is common in children and constitutes a major public health problem, with an impact on patient's health and on medical costs. However, it has been found that most of these reactions are not confirmed by a complete allergic workup. The diagnostic value of the currently available allergy tests has been investigated intensively recently by different groups throughout the world. This has led to major changes in the management of children with a suspected BL allergy. Particularly, it is now well accepted that skin tests can be skipped before the drug provocation test in children with a benign non-immediate reaction to BL. However, there is still a debate on the optimal allergic workup to perform in children with a benign immediate reaction. In addition, management of children with severe cutaneous adverse drug reactions remains difficult. In this review, based on a selection of the most relevant studies found in the literature, we will review and discuss the diagnosis of different forms of BL allergy in children. © 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    An EAACI Task Force report on allergy to beta-lactams in children: Clinical entities and diagnostic procedures
    (2021)
    Blanca-Lopez, Natalia (16835888500)
    ;
    Atanaskovic-Markovic, Marina (6506020842)
    ;
    Gomes, Eva R. (7102464240)
    ;
    Kidon, Mona (10339388800)
    ;
    Kuyucu, Semanur (6602727782)
    ;
    Mori, Francesca (58041318500)
    ;
    Soyer, Ozge (24483981200)
    ;
    Caubet, Jean-Christoph (36460677400)
    Beta-lactam (BL) allergy suspicion is common in children and constitutes a major public health problem, with an impact on patient's health and on medical costs. However, it has been found that most of these reactions are not confirmed by a complete allergic workup. The diagnostic value of the currently available allergy tests has been investigated intensively recently by different groups throughout the world. This has led to major changes in the management of children with a suspected BL allergy. Particularly, it is now well accepted that skin tests can be skipped before the drug provocation test in children with a benign non-immediate reaction to BL. However, there is still a debate on the optimal allergic workup to perform in children with a benign immediate reaction. In addition, management of children with severe cutaneous adverse drug reactions remains difficult. In this review, based on a selection of the most relevant studies found in the literature, we will review and discuss the diagnosis of different forms of BL allergy in children. © 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Diagnosis and management of drug-induced anaphylaxis in children: An EAACI position paper
    (2019)
    Atanaskovic-Markovic, Marina (6506020842)
    ;
    Gomes, Eva (7102464240)
    ;
    Cernadas, Josefina Rodrigues (26021729900)
    ;
    du Toit, George (7004416850)
    ;
    Kidon, Mona (10339388800)
    ;
    Kuyucu, Semanur (6602727782)
    ;
    Mori, Francesca (58041318500)
    ;
    Ponvert, Claude (56188020000)
    ;
    Terreehorst, Ingrid (55888235900)
    ;
    Caubet, Jean-Christoph (36460677400)
    Drug hypersensitivity reactions (DHR) constitute a major and common public health problem, particularly in children. One of the most severe manifestations of DHR is anaphylaxis, which might be associated with a life-threatening risk. During those past decades, anaphylaxis has received particularly a lot of attention and international consensus guidelines have been recently published. Whilst drug-induced anaphylaxis is more commonly reported in adulthood, less is known about the role of drugs in pediatric anaphylaxis. Betalactam antibiotics and non-steroidal anti-inflammatory drugs are the most commonly involved drugs, probably related to high prescription rates. Diagnosis relies on the recognition of symptoms pattern and is based on complete allergic workup, particularly including skin tests and/or specific IgE. However, the real diagnostic value of those tests to diagnose immediate reactions in children remains not well defined for a significant number of the drugs. Generally, a drug provocation test is discussed to confirm or exclude an immediate-onset drug-induced hypersensitivity. Although avoidance of the incriminated drug (and related drug) is the rule, rapid desensitization is useful in selected subgroups of patients. There is a need for large, multicentric studies, to evaluate the real diagnostic value of the currently available skin tests. Moreover there is also a need to develop new diagnostic tests in the future to improve the management of these children. © 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Diagnosis and management of drug-induced anaphylaxis in children: An EAACI position paper
    (2019)
    Atanaskovic-Markovic, Marina (6506020842)
    ;
    Gomes, Eva (7102464240)
    ;
    Cernadas, Josefina Rodrigues (26021729900)
    ;
    du Toit, George (7004416850)
    ;
    Kidon, Mona (10339388800)
    ;
    Kuyucu, Semanur (6602727782)
    ;
    Mori, Francesca (58041318500)
    ;
    Ponvert, Claude (56188020000)
    ;
    Terreehorst, Ingrid (55888235900)
    ;
    Caubet, Jean-Christoph (36460677400)
    Drug hypersensitivity reactions (DHR) constitute a major and common public health problem, particularly in children. One of the most severe manifestations of DHR is anaphylaxis, which might be associated with a life-threatening risk. During those past decades, anaphylaxis has received particularly a lot of attention and international consensus guidelines have been recently published. Whilst drug-induced anaphylaxis is more commonly reported in adulthood, less is known about the role of drugs in pediatric anaphylaxis. Betalactam antibiotics and non-steroidal anti-inflammatory drugs are the most commonly involved drugs, probably related to high prescription rates. Diagnosis relies on the recognition of symptoms pattern and is based on complete allergic workup, particularly including skin tests and/or specific IgE. However, the real diagnostic value of those tests to diagnose immediate reactions in children remains not well defined for a significant number of the drugs. Generally, a drug provocation test is discussed to confirm or exclude an immediate-onset drug-induced hypersensitivity. Although avoidance of the incriminated drug (and related drug) is the rule, rapid desensitization is useful in selected subgroups of patients. There is a need for large, multicentric studies, to evaluate the real diagnostic value of the currently available skin tests. Moreover there is also a need to develop new diagnostic tests in the future to improve the management of these children. © 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    EAACI/ENDA Position Paper: Diagnosis and management of hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) in children and adolescents
    (2018)
    Kidon, Mona (10339388800)
    ;
    Blanca-Lopez, Natalia (16835888500)
    ;
    Gomes, Eva (7102464240)
    ;
    Terreehorst, Ingrid (55888235900)
    ;
    Tanno, Luciana (35575132500)
    ;
    Ponvert, Claude (56188020000)
    ;
    Chin, Chiang Wen (57200009116)
    ;
    Caubet, Jean Christoph (36460677400)
    ;
    Soyer, Ozge (24483981200)
    ;
    Mori, Francesca (58041318500)
    ;
    Blanca, Miguel (56004093600)
    ;
    Atanaskovic-Markovic, Marina (6506020842)
    Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in the pediatric population as antipyretics/analgesics and anti-inflammatory medications. Hypersensitivity (HS) reactions to NSAID in this age group, while similar to adults, have unique diagnostic and management issues. Although slowly accumulating, published data in this age group are still relatively rare and lacking a unifying consensus. This work is a summary of current knowledge and consensus recommendations utilizing both published data and expert opinion from the European Network of Drug Allergy (ENDA) and the Drug Hypersensitivity interest group in the European Academy of Allergy and Clinical Immunology (EAACI). This position paper summarizes diagnostic and management guidelines for children and adolescents with NSAIDs hypersensitivity. © 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    EAACI/ENDA Position Paper: Diagnosis and management of hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) in children and adolescents
    (2018)
    Kidon, Mona (10339388800)
    ;
    Blanca-Lopez, Natalia (16835888500)
    ;
    Gomes, Eva (7102464240)
    ;
    Terreehorst, Ingrid (55888235900)
    ;
    Tanno, Luciana (35575132500)
    ;
    Ponvert, Claude (56188020000)
    ;
    Chin, Chiang Wen (57200009116)
    ;
    Caubet, Jean Christoph (36460677400)
    ;
    Soyer, Ozge (24483981200)
    ;
    Mori, Francesca (58041318500)
    ;
    Blanca, Miguel (56004093600)
    ;
    Atanaskovic-Markovic, Marina (6506020842)
    Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in the pediatric population as antipyretics/analgesics and anti-inflammatory medications. Hypersensitivity (HS) reactions to NSAID in this age group, while similar to adults, have unique diagnostic and management issues. Although slowly accumulating, published data in this age group are still relatively rare and lacking a unifying consensus. This work is a summary of current knowledge and consensus recommendations utilizing both published data and expert opinion from the European Network of Drug Allergy (ENDA) and the Drug Hypersensitivity interest group in the European Academy of Allergy and Clinical Immunology (EAACI). This position paper summarizes diagnostic and management guidelines for children and adolescents with NSAIDs hypersensitivity. © 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback